Nomad Bioscience Enters into a Strategic Partnership with Bayer CropScience

München, (PresseBox) - Nomad Bioscience GmbH, Munich/Halle, Germany (NOMAD), a plant biotechnology company, has announced that the company has entered into a strategic joint research and development agreement with Bayer CropScience, Monheim, Germany.

The multi-year collaboration continues an earlier research program and provides Bayer CropScience broad exclusivity with regard to crop species and plant traits. The financial and other material provisions of the agreement were not disclosed.

Dr. Yuri Gleba, NOMAD's CEO said: "Since the advent of genetically engineered plants that have been first produced in 1982 and commercialized in 1994, this is the only new technology with huge business potential, one that allows to extract value in agriculture in an entirely different way. To bring it to the market is a massive undertaking, and we are extremely happy to have one of the largest agribusiness companies as our strategic partner."

Nomad Bioscience GmbH

NOMAD represents a clear and compelling business and investment proposition that provides partners and investors with both high return potential and low downside risks. Research at NOMAD have demonstrated that green plants can be transiently (non-genetically) modified by simply spraying them with Agrobacteria. The technology is at an early stage of development, and at this time, it carries two kinds of failure risks: technical and regulatory. Both risks are being addressed by NOMAD in a systematic and clearly defined way. NOMAD has achieved a proof of principle by demonstrating efficient expression of several economically important traits. The proposed transient reprogramming of plants is an alternative to genetic transformation of plants, and it has a number of potential advantages. It also is an alternative to using pesticides and agrochemicals as it theoretically allows a much more sophisticated way of protecting plants. NOMAD is currently developing a series of high-value products such as agronomic traits, cellulases and antimicrobial proteins for important markets including agriculture, biofuels, animal health and food preservation. NOMAD has a pipeline of selected product candidates and it intends to have its products on the market within 4-6 years, while producing partnering revenue between now and then.

To learn more, please visit http://www.nomadbioscience.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.